FMP

FMP

Enter

BOLT - Bolt Biotherapeutics...

Financial Summary of Bolt Biotherapeutics, Inc.(BOLT), Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of im

photo-url-https://financialmodelingprep.com/image-stock/BOLT.png

Bolt Biotherapeutics, Inc.

BOLT

NASDAQ

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

1.13 USD

0.0186 (1.65%)

About

ceo

Dr. Randall C. Schatzman Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.boltbio.com

exchange

NASDAQ

Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also develo...

CIK

0001641281

ISIN

US0977021049

CUSIP

097702104

Address

900 Chesapeake Drive

Phone

650 665 9295

Country

US

Employee

100

IPO Date

Feb 5, 2021

Summary

CIK

0001641281

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

097702104

ISIN

US0977021049

Country

US

Price

1.13

Beta

0.99

Volume Avg.

130.27k

Market Cap

43.03M

Shares

-

52-Week

0.84-2.03

DCF

-0.05

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.62

P/B

-

Website

https://www.boltbio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BOLT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep